Emerging pathways can help cell and gene therapies become commercially viable for intractable diseases, even with uneven scalability and consistency.

A little over a year after winning manufacturing certification for its cell therapy factory-in-a-box, South San Francisco’s Cellares has passed another major production milestone. Cellares’ automated ...

Adoptive therapies based on CAR/TCR T cells—that is, T cells with an engineered chimeric antigen receptor (CAR) or a T-cell receptor (TCR)—have shown promise for a range of cancers, offering hope to ...

Cell and gene therapy (CGT) has evolved from a niche research pursuit into a central force in biopharmaceutical innovation. By engineering living cells and genetic material to repair or replace faulty ...

Rusty Konkol wanted to hug everyone he saw during his tour of Iovance Biotherapeutics’ Navy Yard manufacturing facility. The ...

A novel approach to automating cell therapy manufacturing using industry-standard equipment can potentially reduce human errors, deliver higher quality product, and lower manufacturing costs by ...